TSX open
Loading markets…

Advertisement

Stocks

Why Cardiol Therapeutics Inc Class A stock plummeted yesterday

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:CRDL.TO

Follow CRDL

Photos provided by Pexels

Cardiol Therapeutics Inc Class A faced a significant decline in its stock price, raising concerns among investors.

In yesterday's trading session, Cardiol Therapeutics Inc Class A (CRDL.TO) saw its stock price drop by 12.34%, closing at CA$2.77. This sharp decline has left investors questioning the company's stability and future prospects.

Advertisement

Cardiol Therapeutics Inc Class A

CRDL.TO

Full stock page →

CRDL.TO

Cardiol Therapeutics Inc Class A

Source:WealthAwesomeWealthAwesome
↓ $0.02 (-1.03%)
120 day period
$1.44$2.30$3.16Apr 15Jul 10Oct 5

Market cap

$234.52M

52W high

$3.23

52W low

$1.23

1W change

-19.25%

Beta

0.72

Analyst Price Targets

Based on analyst covering CRDL · as of Sep 17, 2026

📈

Wall Street analysts forecast CRDL stock price to rise 354.5% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$6.00

+354.5% Upside

Current Price

C$1.32

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on CRDL's historical volatility

HistoricalForecast68%95%
C$0.89C$1.91C$2.92C$3.93C$4.94C$5.95TodayMay 28Jul 31Oct 5Nov 17Dec 31Feb 12

30-Day Vol

76.8%

Annualized

90-Day Vol

66.2%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$2.31

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$2.05C$1.57 – C$2.67
60 trading daysC$2.17C$1.49 – C$3.16
90 trading daysC$2.31C$1.46 – C$3.65

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Investors should closely monitor Cardiol Therapeutics as the recent drop in stock price may indicate underlying issues or shifts in market sentiment.

12.34% decline in stock price

Cardiol Therapeutics Inc Class A's market cap now stands at CA$369 million, a significant drop from previous valuations.

Bull case

Despite the recent downturn, Cardiol Therapeutics is actively engaging with investors and participating in major conferences. These efforts could enhance its visibility and attract future investment.

Bear case

The 12.34% drop in stock price reflects investor concerns about the company's performance and potential challenges ahead, especially given the lack of recent positive news.

Recent Performance Overview

Advertisement

Cardiol Therapeutics faced a challenging trading day yesterday, with its stock price falling by 12.34%. This decline raises questions about investor confidence and the company's current standing in the market. The drop in share price has brought the market cap down to CA$369 million, highlighting the volatility often seen in smaller biotech firms.

Market Sentiment and Future Outlook

The lack of recent positive news from Cardiol Therapeutics could be contributing to the negative sentiment surrounding the stock. Investors are urged to consider the implications of this drop and to stay informed about any upcoming announcements or developments that could influence the company's trajectory. Historically, biotech stocks can be highly reactive to news, making it crucial for investors to monitor the situation closely.

What Investors Should Watch For

As Cardiol Therapeutics navigates this downturn, investors should keep an eye on any future presentations or data releases that could shift market sentiment. The company's participation in events like the H.C. Wainwright 28th Annual Global Investment Conference may provide opportunities for recovery, but caution is advised given the current volatility. For more insights, check out the Cardiol Therapeutics stock page for updates.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: September 11, 2026
Last Updated: October 2, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement